The Jubilant Group is a diversified Indian conglomerate with a robust presence throughout a number of sectors, together with meals providers, prescribed drugs, life sciences, and specialty chemical substances. The group operates marquee manufacturers corresponding to Domino’s Pizza, Dunkin’ Donuts, and Popeyes via its meals enterprise, whereas additionally being a big participant in prescribed drugs, contract manufacturing and specialty chemical substances.
With a concentrate on each home progress and worldwide market alternatives, the Jubilant Group continues to leverage strategic investments, superior R&D, and operational scale to ship long-term worth to shareholders and set up management throughout its various enterprise portfolio.
Listed here are three shares from the Jubilant Group to maintain in your radar, chosen based mostly on latest developments and strategic initiatives that might drive their progress within the close to to medium time period.
Jubilant FoodWorks Restricted (JFL), a distinguished a part of the Jubilant Bhartia Group, has positioned itself as one in every of India’s main meals service corporations. The corporate operates marquee manufacturers together with Domino’s Pizza, Dunkin’ Donuts, Popeyes, Hong’s Kitchen, and Coffy, creating a various footprint throughout pizza, espresso, hen, and Chinese language delicacies.
With aggressive growth each domestically and internationally, JFL continues to consolidate its management within the quick-service restaurant (QSR) sector. The corporate’s present market capitalization stands at Rs. 38,963.86 crore, with its inventory buying and selling at Rs. 590.50.
During the last 12 months (based mostly on Q1FY26), JFL added 330 new shops, of which Domino’s accounted for 265 retailers, pushing the full retailer rely to three,387. In Q1FY26 alone, the corporate launched 71 shops, together with 67 Domino’s retailers, reinforcing its stronghold within the Indian QSR market.
As of June thirtieth, Domino’s operates 2,240 shops throughout 484 cities, reflecting each city-level growth and strong order progress. The model reported a 17.7 % year-on-year income progress in Q1FY26, with order volumes up 17.3 %, pushed by an 11.6 % like-for-like progress.
Supply continues to be a significant progress driver, with supply income rising 24.6 % and order volumes rising 25.7 % year-on-year, whereas mature retailer common every day gross sales stood at Rs. 85,396. The dine-in section grew modestly by 2.5 %, largely led by lunch-hour site visitors.
JFL’s digital platforms additional strengthen its progress trajectory, with the Domino’s app recording 14.7 million month-to-month lively customers (up 21.5 % year-on-year), 12.3 million installs (up 19.4 %), and a loyalty base of 37 million prospects.
Popeyes has expanded to 60 eating places throughout 23 cities, with Southern India seeing double-digit same-store gross sales progress, whereas Coffy in Turkey has grown to 167 cafes throughout 38 cities, steadily enhancing its profitability.
In Q1FY26, India section Domino’s progress contributed to general income growth of 17.7 %, with delivery-led same-store gross sales up 20.1 %. EBITDA margins expanded by 42 foundation factors year-on-year, although gross margins fell 199 foundation factors attributable to greater funding in progress and delivery-driven gross sales combine. Product improvements, together with the Cheese Burst Vary, Huge Huge Pizza, and Rooster Burst, supported income progress.
JFL’s worldwide operations additionally confirmed momentum, with Turkey’s system gross sales rising 19.1 % to Rs. 9,300 million and PAT at Rs. 486 million, up 15 %. Sri Lanka and Bangladesh revenues grew 42.4 % and 4.3 %, respectively, reflecting strategic abroad growth. Yr-on-year, JFL’s income elevated from Rs. 1,933 crore to Rs. 2,261 crore, working revenue rose from Rs. 380 crore to Rs. 438 crore, revenue earlier than tax climbed from Rs. 77 crore to Rs. 126 crore, and web revenue surged from Rs. 58 crore to Rs. 94 crore.
Jubilant Pharmova Restricted, previously Jubilant Life Sciences, is a worldwide pharmaceutical and life sciences firm working in Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, CRDMO, Generics, and Proprietary Novel Medicine. The corporate’s operations span a number of geographies, together with the US, Europe, and different regulated markets, with a workforce of roughly 5,500.
Jubilant Pharmova is recognised globally as a trusted associate by main pharmaceutical corporations. The inventory at present trades at Rs. 1,118.20, with a market capitalization of Rs. 17,810.82 crore.
The corporate not too long ago commissioned a New Sterile Fill & End line at Jubilant HollisterStier LLC (JHS), its wholly-owned North American subsidiary, marking the third line at its Spokane, Washington facility. This growth provides 50 % extra capability, utilising superior isolator expertise for enhanced sterility, operational precision, and regulatory compliance.
The US$ 132 million funding underlines the corporate’s long-term dedication to innovation and provide chain resilience. JHS plans to double its whole sterile injectable manufacturing capability with the upcoming fourth line, additional consolidating its home US market management whereas supporting onshore manufacturing wants and nationwide well being safety.
The CDMO Sterile Injectables section witnessed a 14 % income progress to Rs. 370 crore in Q1FY26, with EBITDA up 9 % to Rs. 62 crore, regardless of non permanent margin compression from an annual upkeep shutdown.
Massive innovator pharmaceutical corporations are more and more in search of alternate US manufacturing websites to mitigate tariff dangers, driving sturdy traction in Requests for Proposals (RFPs) for Line 3. Peak utilization is now anticipated inside three years, sooner than the initially projected 4.
In line with Fitch, the CSI and CRDMO segments are poised to be progress drivers for Jubilant Pharmova, with deliberate capex of USD 285 million and USD 40 million for the respective segments over FY23-FYE26. The corporate anticipates incremental revenues from CDMO capability growth beginning FY26, with wholesome order e-book traction from multinational pharma gamers.
The CSI enterprise advantages from a possible international vial supply-demand hole of 700 million models in 2027, together with the patent expiry of a number of medicine and biologics. Yr-on-year, Jubilant Pharmova’s gross sales rose 9.79 % to Rs. 1,901 crore in Q1FY26, Working Revenue elevated 15.08 % to Rs. 290 crore, whereas PBT and web revenue declined 69.2 % and 78.84 % to Rs. 154 crore and Rs. 102 crore, respectively.
Additionally learn: 2 Shares to purchase now for an upside of as much as 27%; Advisable by Commerce Brains Portal
Jubilant Ingrevia Restricted is a globally built-in life sciences and specialty chemical substances firm serving pharmaceutical, diet, agrochemical, shopper, and industrial prospects. With over 130 merchandise and customised options, it’s a main international participant in Pyridine, Picolines, Acetic Anhydride, Vitamin-B3, and different specialty chemical substances.
The corporate operates 50 manufacturing services in India with a workforce of over 2,300 staff, supported by three R&D centres using 150 scientists. Jubilant Ingrevia has additionally expanded its CDMO choices to the pharmaceutical, agrochemical, and semiconductor sectors, focusing on high-technology purposes and international provide chain priorities. Its present inventory worth is Rs. 676.60, with a market capitalization of Rs. 10,776.96 crore.
Jubilant Ingrevia’s merchandise function key intermediates for purposes together with water fabrication, efficiency inks, and X-ray distinction brokers. Its Beta Picoline, 3,5-Lutidine, Pyridine, and Choline discover use throughout the semiconductor and polyimide movie industries, whereas its specialty chemical substances are utilized in antimicrobial textiles. The corporate has additionally expanded into customized synthesis for photoresists, photo-acid mills, and anti-reflective coatings, catering to high-technology chemical purposes.
The corporate’s CDMO enterprise continues to broaden, with important progress within the pharmaceutical section. The chance pipeline has doubled in latest months, pushed by sturdy traction with progressive pharma corporations and Tier-1 CDMOs throughout the US, EU, and Japan. Within the agrochemical section, deliveries for the primary contract have commenced, and progress continues on the second, alongside ongoing discussions with innovators.
The semiconductor section now has over 12 lively alternatives within the pipeline, reflecting rising international curiosity. Jubilant Ingrevia is strategically investing in R&D and devoted groups to strengthen capabilities and assist rising markets.
Over the previous two years, the corporate has developed platforms starting from diketene derivatives to cosmetic-grade nutritional vitamins and recognized new alternatives in semiconductor and beauty industries, accelerating product launches, scaling established franchises, and coming into nascent markets to generate a number of income streams.
Written by – Manan Gangwar
